This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feinberg, A. P. Search for Related Content PubMed PubMed Citation Articles by Feinberg, A. P.

Imprinting of a Genomic Domain of 11p15 and Loss of Imprinting in Cancer: An Introduction¹

Departments of Medicine, Oncology, and Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

² To whom requests for reprints should be addressed, at Johns Hopkins University School of Medicine, 1064 Ross, 720 Rutland Avenue, Baltimore, MD 21205.

Our laboratory has found genomic imprinting of a large genomic domain of human 11p15.5, identifying six imprinted genes within this domain: (a) insulin-like growth factor II (IGF-II), an important autocrine growth factor in a wide variety of malignancies; (b) H19, an untranslated RNA that is a putative growth suppressor gene regulating IGF-II; (c) p57^KIP2, a cyclin-dependent kinase inhibitor that causes G₁-S arrest; (d) K_VLQT1, a voltage-gated potassium channel; (e) TSSC3, a gene that is homologous to mouse TDAG51, which is implicated in Fas-mediated apoptosis; and (f) TSSC5, a putative transmembrane protein-encoding gene. We hypothesize that 11p15 harbors a large domain of imprinted growth-regulatory genes that are important in cancer. Several lines of evidence support this hypothesis: (a) we have discovered a novel genetic alteration in cancer, loss of imprinting, which affects several of these genes, and is one of the most common genetic changes in human cancer; (b) we have found that the hereditary disorder Beckwith-Wiedemann syndrome, which predisposes to cancer and causes prenatal overgrowth, involves alterations in p57^KIP2, IGF-II, H19, and K_VLQT1; (c) we have found both genetic (somatic mutation in Wilms' tumor) and epigenetic alterations (DNA methylation) in cancer; and (d) we can partially reverse abnormal imprinting using an inhibitor of DNA methylation. We propose a model of genomic imprinting as a dynamic developmental process involving a chromosomal domain. According to this model, cancer involves both genetic and epigenetic mechanisms affecting this imprinted domain and the genes within it.

¹ Presented at the "General Motors Cancer Research Foundation Twentieth Annual Scientific Conference: Developmental Biology and Cancer," June 9–10, 1998, Bethesda, MD. This work was supported by NIH Grant CA65145.

Received 12/ 4/98. Accepted 2/ 1/99.

This article has been cited by other articles:

				T. Yoshimizu, A. Miroglio, M.-A. Ripoche, A. Gabory, M. Vernucci, A. Riccio, S. Colnot, C. Godard, B. Terris, H. Jammes, et al. The H19 locus acts in vivo as a tumor suppressor PNAS, August 26, 2008; 105(34): 12417 - 12422. [Abstract] [Full Text] [PDF]

				M. Esteller Epigenetics in Cancer N. Engl. J. Med., March 13, 2008; 358(11): 1148 - 1159. [Full Text] [PDF]

				A.P. FEINBERG A Genetic Approach to Cancer Epigenetics Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 335 - 341. [Abstract] [PDF]